RE:RE:RE:Just how much market share is TOS taking from ASP (JnJ)?Btw, just what is TOS worth to the present low temp market leader JnJ? 1st, to gain a bit of context for those who have not yet done so, go through in detail the March 22 TSO3 Presentation on the web site. And, read the basic patent info by linking to at least the first patent listed at the bottom of the first intro slide. The patents establish the Moat for TSO3, a la Graham. Once FDA makes the move to establish sterilization as the standard of care for scopes in general, and gives TSO3 extended claims for specific scopes on a case by case basis such as the Olympus Q180V, the stunning superiority of the VP4, and a new smaller OR suite model, will be a given. It is the unique TSO3 ozone on H2O2 that gives ut the ability to sterilize lumens and instruments that the competition cannot and will not ever be able to sterilize. And, as rumours have it that JnJ is already 'stepping back' in this space, what valuation would JnJ placebon TSO3? With a 47% profit margin on sales of 1000-2000 units per year, as market replacements for the inferior Sterrad and Steris models and with a similar minimum number of NEW installs required by N. Americsn hospitals to meet FDA standards, plus the ongoing consumables... EPS will be in the $2 - 4 range.
So what is this company doing with a ridiculous market cap of only $200,000,000, when it should see at least 10 x that valuation, especially as a take-out target and cash-cow for a market leader like JnJ? I am scratching my head, quite frankly. And, smiling... It is a very blue sky!! WKH